Research Article| Volume 37, ISSUE 11, P2560-2571, November 01, 2015

Download started.


Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects



      The 2 direct-acting antiviral combination (2D) of ombitasvir and paritaprevir (coadministered with ritonavir) is being evaluated for the treatment of chronic hepatitis C virus infection in Japan. Ursodeoxycholic acid (UDCA) and glycyrrhizin (GCR) are hepatoprotective agents widely used in Japan. A drug-drug interaction (DDI) study was conducted to guide dosing recommendations for UDCA and GCR when coadministered with the 2D regimen.


      DDIs between the 2D regimen (ombitasvir/paritaprevir/ritonavir 25/150/100 mg orally once daily) and UDCA (50 mg orally 3 times daily) or GCR (80 mg intravenously once daily) were evaluated in a 2-arm, multiple-dose study in 24 Japanese healthy subjects under fed conditions. Pharmacokinetic and safety evaluations were performed when UDCA or GCR and the 2D regimen were administered alone and during coadministration. Exposures from coadministration of the 2D regimen plus UDCA or GCR versus the 2D regimen, UDCA, or GCR alone were compared using repeated-measures analyses of natural logarithms of the maximum plasma concentration (Cmax) and area under the curve (AUC).


      After coadministration of the 2D regimen and UDCA, steady-state exposures (Cmax and AUC) of ombitasvir, paritaprevir, and ritonavir showed a ≤9% change, and UDCA exposures showed a ≤20% change compared with administration alone. When the 2D regimen and GCR were coadministered, steady-state exposures of ombitasvir, paritaprevir, and ritonavir were not affected (≤9% change), GCR AUC increased by 49%, and GCR Cmax was unaffected (<1% change).


      No dose adjustment is needed for UDCA, GCR, or the 2D regimen when UDCA or GCR is coadministered with the 2D regimen in hepatitis C virus–infected patients under fed conditions. Clinical monitoring of patients using GCR is recommended due to an approximately 50% increase in GCR AUC when coadministered with the 2D regimen.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. World Health Organization. Hepatitis C Fact Sheet 164. Updated April 2014. [Cited 10 July 2015].

      2. Kohnodai Hospital. National Center for Global Health and Medicine. [Cited 10 July 2015].

        • Okamoto H.
        • Mishiro S.
        Genetic heterogeneity of hepatitis C virus.
        Intervirology. 1994; 37: 68-76
      3. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. [Cited 10 July 2015].

        • Sievert W.
        • Altraif I.
        • Razavi H.A.
        • et al.
        A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.
        Liver Int. 2011; 31: 61-80
        • Chung H.
        • Ueda T.
        • Kudo M.
        Changing trends in hepatitis C infection over the past 50 years in Japan.
        Intervirology. 2010; 53: 39-43
        • Chayama K.
        • Notsumata K.
        • Kurosaki M.
        • et al.
        Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.
        Hepatol. 2015; 61: 1523-1532
        • Kumada H.
        • Chayama K.
        • Rodrigues Jr, L.
        • et al.
        Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.
        Hepatol. 2015; 62: 1037-1046
        • Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology
        JSH guidelines for the management of hepatitis C virus infection: A 2014 update for genotype 1.
        Hepatol Res. 2014; 44: 59-70
        • Scalia S.
        • Scagliarini R.
        • Pazzi P.
        Evaluation of ursodeoxycholic acid bioavailability from immediate- and sustained-release preparations using gas chromatography-mass spectrometry and high-performance liquid chromatography.
        Arzneimittelforschung. 2000; 50: 129-134
        • Crosignani A.
        • Setchell K.D.
        • Invernizzi P.
        • et al.
        Clinical pharmacokinetics of therapeutic bile acids.
        Clin Pharmacokinet. 1996; 30: 333-358
        • Scalia S.
        • Giunchedi P.
        • Pazzi P.
        • Conte U.
        Enhancement of ursodeoxycholic acid bioavailability by cross-linked sodium carboxymethyl cellulose.
        J Pharm Pharmacol. 2000; 52: 383-388
      4. Urso® Tablets [package insert]. Kitahama, Chuo-ku, Osaka: Mitsubishi Tanabe Pharma Corporation.

      5. Urso 250® and Urso Forte® Tablets [US package insert].
        Aptalis Pharma US, Inc, Bridgewater, NJ2013
      6. Stronger Neo-Minophagen C® [package insert]. Akasaka, Tokyo, Japan: Minophagen Pharmaceutical Co., Ltd.

        • Sasaki M.
        • Maeda A.
        • Sakamoto K.
        • Fujimura A.
        Effect of bile acids on absorption of nitrendipine in healthy subjects.
        Br J Clin Pharmacol. 2001; 52: 699-701
        • Stroubou E.
        • Dawn G.
        • Forsyth A.
        Ursodeoxycholic acid causing exacerbation of dermatitis herpetiformis.
        J Am Acad Dermatol. 2001; 45: 319-320
        • Hempfling W.
        • Dilger K.
        • Beuers U.
        Systematic review: ursodeoxycholic acid--adverse effects and drug interactions.
        Aliment Pharmacol Ther. 2003; 18: 963-972
        • Yan M.
        • Fang P.F.
        • Li H.D.
        • et al.
        Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers.
        Eur J Clin Pharmacol. 2013; 69: 515-521
        • Tu J.H.
        • He Y.J.
        • Chen Y.
        • et al.
        Effect of glycyrrhizin on the activity of CYP3A enzyme in humans.
        Eur J Clin Pharmacol. 2010; 66: 805-810
      7. Bow DAJ, Liu J, Kavetskaia O, et al. A Mechanistic non-clinical assessment of drug-drug interactions (metabolism and transporters) with the hepatitis C virus (HCV) regimen: ABT-450/r, ombitasvir and dasabuvir. Poster presented at: 2014 American Association for the Study of Liver Diseases/European Association for the Study of the Liver Special Conference on Hepatitis C; September 12–13, 2014; New York, NY.

      8. Viekira Pak ™[US package insert].
        AbbVie, Inc, North Chicago, IL2015
        • Sontia B.
        • Mooney J.
        • Gaudet L.
        • Touyz R.M.
        Pseudohyperaldosteronism, liquorice, and hypertension.
        J Clin Hypertens (Greenwich). 2008; 10: 153-157